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Abstract
Introduction: Basal cell carcinoma (BCC) is the most prevalent form of non-melanoma skin cancer 
commonly arising in elderly patients. Currently, many laser systems are applied for the treatment 
of BCC. However, up to the present, there have been several reports concerning ocular side effects 
due to the laser procedure in the borders of the periorbital area. This determines the feasibility 
of testing new laser surgical modes for the management of periorbital BCC. This stuay aimed to 
estimate both the efficacy, the early post-radiated side effects and long-term outcomes of the CVL 
treatment of periorbital BCC.
Patients and Methods:  Two men and 6 women aged 50 to 77 years were diagnosed with periorbital 
BCC according to the data of both the clinical evaluation and histological examination of the 
tissue samples taken from the involved area. Six months after the laser treatment, the histological 
examination of skin samples from the borderline of the irradiated area was made again. All patients 
were followed for 24 months after the laser treatment of BCC. The laser treatment was administered 
during one session of copper vapor laser (CVL) (Yakhroma-Med model). The treatment included 
CVL radiation with a wavelength of 511 nm and 578 nm, in the ratio of 3:2. The power level was 
set up to 3 W, and the exposure time was equal from 200 to 600 ms. The pulse duration accounted 
for 15 ns. The diameter of the light spot on the skin surface amounted to 1 mm.
Results: Dual-wavelengths CVL treatment of periorbital BCC provided a complete elimination of 
malignant cells and dysplastic vessels during one procedure. The duration of skin healing amounted 
to 2-4 weeks. There were neither ocular injuries or pronounced skin side effects nor relapses within 
24 months after the laser procedure. 
Conclusion: CVL treatment of periorbital BCC provides relevant cosmetic results without ocular 
injuries and relapses. 
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Introduction
Occurred mostly in fair skin people, basal cell carcinoma 
(BCC) is commonly located at the face, including 
periorbital area. BCC was proved to be related to the 
ultraviolet radiation (UVR) damage of mitochondrial 
and nuclear DNA in keratinocytic stem cells of the 
epidermal basal layer.1 The sun exposure damage to basal 
keratinocytes is mediated via the UVR absorption by 
DNA with the following extgeneration of free radicals and 
mitochondrial oxidative stress.2 Following both nuclear 
DNA and mitochondrial RNA impairments along with 
PARP insufficiency are known to deteriorate as the natural 
behavior of epidermal basal melanocytes and keratinocytes 
as their interaction with related sebocytes and endothelial 
cells.3-5 So far the pathogenesis of BCC is associated 
with both dysfunction of keratinocytes and melanocytes 
of the basal layer of the epidermis and the abnormal 
transformation of the vascular bed in the BCC underlying 
papillary dermal layer.6-8 According to the data reported in 
recent bench-to-bedside investigations, the pathogenetic 
treatment of BCC must provide the elimination of both 
all-malignant keratinocytes and melanocytes supporting 
the progression of the malignant process in the basal layer 
of the epidermis and the pathological vascular dysplastic 
bed in the adjacent dermal papillary layer. Up to the 
present, there has been appeared a number of reports 
concerning the sound application of such laser systems 
as pulsed dye laser, diode, Nd:YAG, and CO2 laser system 
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for the treatment of BCC. These systems allow in many 
cases achieving the complete regression of primary BCC 
at the stage of T1-2N0M0.
9 Whereas some laser systems 
use the radiation that is not mostly absorbed by neither 
melanin nor oxyhemoglobin, laser light can reach the 
reticular layer of the dermis or even deeper to cause such 
ocular injuries as pain above and behind the eye, blurred 
vision, and photophobia.10 Thus it seems important to 
adopt new modes of laser surgical treatment management 
of BCC located near an eye. 
As mentioned above, the use of the dual-wavelength 
copper vapor laser (CVL) radiation seems to be promising 
for the relevant pathogenetic laser treatment of BСС, as 
the CVL radiation with a wavelength of 511 nm, mainly 
absorbed by melanin, promotes the elimination of the 
malignant basaloid cells. The radiation with the wavelength 
of 578 nm, mostly absorbed by oxyhemoglobin and 
deoxyhemoglobin, provides the complete photothermal 
occlusion of the BCC ectatic vascular bed in the papillary 
dermal layer. Due to the high absorption of 511 nm CVL 
radiation by melanin and 578 nm CVL radiation by 
oxyhemoglobin and deoxyhemoglobin, the penetration 
of CVL laser limited by the dermal papillary layer prevent 
the ocular exposure to laser light. 
Patients and Methods 
Two men and 6 women, aged 50 to 77 years, were 
diagnosed with BCC at the T1-2N0M0 stage according to 
clinical evaluation and histological examination of tissue 
samples taken from the affected area and the borderline 
zone (Table 1). BCC was located at the lower eyelid in four 
cases, at the upper eyelid in 2 cases, at the nasal bridge 
close to the eye corner in one patient, and under the 
eyebrow in 1 case (Figurs 1-5). The BCC was detected to 
be of the nodular subtype in 7 cases and the infiltrative 
subtype in the one patient. The informed consent for the 
laser treatment of BCC with CVL was obtained from all 
patients. The BCC treatment was performed under local 
infiltration anesthesia with Sol. Articaine hydrochloride 
4% with 1:200 000 epinephrine in a dose of 1.7 mL. Just 
after the procedure, a dry scab was formed immediately 
(Figure 1a). The skin was treated with chlorhexidine; 
then, the epithelizing gel was applied 2 times a day until 
the crust fell off. 
Six months after the laser treatment in all the treated 
patients, the tissue samples from the borderline of a 
post-radiated area were examined (1) for the presence of 
atypical cells. All patients were followed for 24 months 
after the laser treatment.
Laser Surgical Technique 
The laser treatment was performed with the use of 
Table 1. Description of patients
No. Age (y) Gender Location Histological Subtype Dimensions (mm) Healing Time (wk)
1 68 Female Inferior eyelid right  Nodular 5 х 4 2
2 51 Male Nasal bridge left Nodular 8 х7 2
3 77 Female Inferior eyelid left  Nodular 5 х 5 3
4 45 Female Upper eyelid left Nodular 10 х 7 3
5 60 Female Under the eyebrow left Nodular 15 х 12   3
6 34 Female Upper eyelid left Ulcerative 10 х 8 2
7 40 Female Inferior eyelid left Nodular 3 х 3 2
8 50 Male Inferior eyelid left Nodular 7 х 9 3
Figure 1. (a) BCC on the right lower eyelid before and immediately 
after CVL treatment (Patient #1 Table 1 Stage IA (T1N0M0)). (b) The 
post-treated area on the right lower eyelid 5 months after the laser 
procedure.
Figure 2. Nodular BCC on the nasal bridge, left, before (a) and 2 
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CVL (Yakhroma-Med model developed at the Lebedev 
Physical Institute of the Russian Academy of Sciences). 
The affected area was irradiated with dual-waves laser 
light of 511 and 578 nm in the ratio of 3:2 in the pulsed 
mode with a train of pulses with the duration of 15 ns 
and a repetition rate of 16.6 kHz. The average power 
was set up at 3 W with an exposure time ranging from 
200 to 600 ms. The fluence ranged from 30 to 300 J/cm2. 
Laser radiation was focused on the patient’s skin in a light 
spot with a diameter of 1 mm. Safety shields were used 
to protect the patients’ eye during the procedure. All the 
involved area and adjacent tissue of 5 mm along with the 
total borderline of the surrounding intact skin area were 
irradiated. The treatment was implemented during one 
CVL session.
Results
According to the clinical examination, after the healing of 
the post-radiated area, the complete BCC regression was 
achieved in all cases (Figures 1-5, b). In the early post-
radiated period, there were neither noted pronounced side 
effects nor ocular injuries. The procedure was followed 
by a mild swelling resolved after two days. The healing 
time lasted for 2 and 3 weeks (Table.1). In the involved 
area, flat atrophic hypopigmented scars instead of BCC 
were formed (Figures 1-5 b). In the tissue samples taken 
6 months after the laser procedure from the borderline 
around the affected post-radiated area, neither basaloid 
cells nor disfigured keratinocytes were found.
No recurrences was observed during the entire 
observation period up to 24 months after treatment. All 
patients expressed satisfaction with the cosmetiс effects 
of the CVL treatment.
Discussion
Several various modes of the management of skin BCC 
have been reported. 
Laser parameters used for the BCC treatment are 
presented in Table 2. The high efficiency of the laser 
destruction of BCC was observed at the first stage of 
tumor development.11 The prevalence of BCC recurrences 
varied up to 15%12 in the first 5 years after removal by 
laser destruction.
Nevertheless, there is no available report concerning 
the laser treatment of BCC located in the periocular 
area. Up to the present time, the laser procedures in the 
vicinity of the periocular zone have been reported to be 
related to the risk of ocular injuries involving the sore eye, 
blurred vision, photophobia, damage to iris, conjunctival 
injection, endothelial keratic precipitates, and cells in 
the anterior chamber.10-18 Compared the above data 
from CVL treatment of periorbital BCC with the rate 
of ocular injuries due to the facial laser procedure with 
other lasers, CVL treatment seems to be safer, as the use 
of another laser in facial cosmetic treatment is reported 
to be associated with ocular injury rate of 33%, χ2=3.515, 
P<0.06 19 .
Abnormal blood vessels of increased diameter, which 
are essential for the delivery of oxygen and nutrients to the 
growing BCC,20-21 can be selectively coagulated by a laser 
using the principle of selective photothermolysis. To date, 
the effectiveness of a pulsed dye laser (PDL), which has 
been successfully used for the selective photodestruction 
of vessels of increased diameter as a non-surgical method 
for the treatment of BCC, has been confirmed in some 
studies 12-14. Despite the relatively low frequency of 
metastasis of BCC,22 a recurrence rate after the PDL 
treatment ranges from 5 to 10 %, which is attributed by 
the authors9 to the insufficient energy exposure provided 
by the PDL.
In a clinical study,15 small-sized <6 mm superficial BCC 
was successfully cured with a diode laser at a wavelength 
of 980 nm with an energy exposure (fluence) in the range 
from 200 to 800 J/cm2 and with an exposure time of 0.1-1 
seconds.
CVL with a wavelength of 578 nm has the optimal 
parameters for the treatment of such vascular lesions 
as port-wine stains, hemangiomas, and telangiectasia.23 
Therefore, the use of CVL, which allows for the selective 
heating of blood vessels, seems reasonable for the 
Figure 3. Nodular BCC on the left lower inferior eyelid, left, before (a) 
and three months after (b) CVL treatment. (Patient #3 Table 1). Stage 
IA (T1N0M0). 
Figure 4. Nodular BCC under the left eyebrow, before (a) and 2 months 
after (b) CVL treatment. (Patient #4 Table 1). Stage I (T1N0M0). 
Figure 5. Nodular BCC on the periocular zone, before (a) and 3 months 
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treatment of BCC.
We compared the heating of vessels and perivascular 
tissue exposed to the radiation generated by CVL or the 
Diode laser. The comparison was based on the procedure 
of the simulation of blood vessel heating using Matlab 
software. The simulation relied upon the solution of 
partial differential equations with Femlab software and 
the use of the finite element method described in our 
previous reports.24
Figure 6 shows the calculated levels of the maximum 
tissue temperature at different depths under CVL and 
diode laser exposure. Due to the localization of the tissue 
heating, corresponding to the location of the BCC, the use 
of CVL seems to be a preferred variant of exposure than 
the diode laser. CVL provides higher tissue temperatures 
at commonly used fluence levels. The deep layers of tissue 
are not damaged, which increases the healing rate after 
the procedure.
Numerical simulation24 showed that the vessels of 
increased diameter to be heated by the CVL radiation 
more stronger than the surrounding tissue. For this 
reason, malignant BCC, which is characterized by 
high vascularization,20-21 is always heated by CVL laser 
radiation to a greater extent in comparison with healthy 
tissue. This effect provides an additional selectivity of the 
laser effect of the CVL for heating the BCC.
The treatment of the nasal BCC with a diode laser was 
related to the recurrence rate in the case of the nodular 
subtype from 19,3 to 50% and as much as 100% in an 
infiltrative subtype of BCC.15 As can be seen from Figure 
6, the calculated temperature of the tissue for a diode 
laser had a little change up to several mm from the skin 
surface. At the same time, more deeply located layers 
were exposed to excessive heating, which made the use of 
a diode laser unsafe, especially in the eye region. 
Moskalik et al17 also indicated that due to the risk 
of damage to the organs of vision, the Nd: YAG laser 
treatment was prohibited for early forms of BCC localized 
on the eyelids. They also noted that one of the conditions 
for the successful treatment of skin cancer is exposure to 
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No. of Treatment 
Sessions
Side-Effects Ref
CO2 29-93 Up to 23 10,600 nm, 750 μs, 7.5 J/cm
2 No 
information
1 No information 13
PDL 29-88 6 595 nm, 3 ms 7.5 J/cm2 4 weeks 1 Purpura 14
PDL 30-90 5 595 nm, 3 ms, 15 J/ cm2 3–4 weeks 1-4
Erythema Purpura, crusts 
- post-inflammatory 
hypopigmentation for 3 
months
12 
Diode 35-91 < 6 
980 nm 0.1-1 s, 200-800 J/cm2, 
0.2-0.9 s
7-10 days 1 Pain 15 
Nd:YAG 30-90 5 
1,060 nm, 125-140 J/cm2, 7-10 
ms, 1.5-4.5 ms, 150–400 J/cm2
30 days Pain 16,17
Figure 6. The calculated temperature distribution of the tissue at the 
end of the laser pulse(600 ms pulse duration) for the CVL (511 nm and 
578 nm) and the diode laser (980 nm), the fluence value and exposure 
time are shown in the graph.
laser radiation on the entire mass of the tumor.
At the same time, due to the high absorption of 578 
nm wavelength by the blood, which falls into the high 
absorption band of hemoglobin, the CVL radiation 
allows working safely in the periorbital region, which was 
also demonstrated in our work. Therefore, the use of CVL 
ablative regime for BCC treatment is reasonable.
Conclusion
The use of high-energy CVL irradiation makes it possible 
to achieve significant success in treating patients with 
BCC in the periorbital region. The use of CVL on an 
outpatient basis may have some advantages in facilitating 
the introduction of this type of laser into medical practice.
The use of CVL causes minimal cosmetic losses; as a 
result, it has significant advantages over other methods 
of treatment.
According to our research, CVL is an effective 
treatment for skin cancer at the stage of T1-2N0M0 and 
provides excellent cosmetic results, including cases in the 
periorbital area.
Klyuchareva et al
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We recommend that a CVL treatment should be used as 
primary therapy for BCC.
CVL treatment offers some advantages as follows: 
• The selective absorption of the laser energy by the 
blood-filled tissue allows selective photo destruction 
of the lesion under ideal hemostatic conditions with 
minimal loss of normal tissue. 
• The laser treatment can be performed under local 
anesthesia on an outpatient basis.
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